Perspective Therapeutics licenses Mayo Clinic's PSMA Alpha-PET platform for up to $68M milestones

Perspective Therapeutics, Inc.

Upfront cash payment of $1M due within 60 days of Dec 22, 2023; milestone payments up to $68M tied to clinical, regulatory, and commercialization achievements.
Single-digit royalties on net sales of certain Licensed Product components; 40% of any PRV sale proceeds to be shared with Mayo.
Platform uses 64/67 Cu and 203/212 Pb double chelator design for PET imaging and alpha/beta-particle targeted RPT.
Preclinical data showed favorable salivary gland uptake and kidney clearance vs. comparators; initial focus on PSMA-expressing prostate cancer.
Mayo Clinic holds financial interest in the technology; Perspective must use commercially reasonable efforts to bring Licensed Products to market.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Perspective Therapeutics, Inc. entered into Exclusive Patent License Agreement with Mayo Foundation for Medical Education and Research valued at upfront payment of $1 million, milestone payments up to $68 million, single digit royalties on net s (effective 2023-12-31).

Action: entry
Agreement: license
Counterparty: Mayo Foundation for Medical Education and Research
Value: upfront payment of $1 million, milestone payments up to $68 million, single digit royalties on net s
Effective: 2023-12-31

Exact text from the filing

On December 31, 2023, Perspective Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into an exclusive patent license agreement (the “ License Agreement ”) with the Mayo Foundation for Medical Education and Research (“ Mayo Clinic ”).

View on SEC.gov

230 material agreements filed in the last 30 days. Browse all material agreements →

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-000752

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.